Novel macrolactam compounds

A compound of formula II,

• and an enantiomer, diastereomer, tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein:
• R1 is hydrogen, halogen, cyano, nitro, CF3, OCF3, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, heterocycle, substituted heterocycle, aryl, substituted aryl, (═O), ORa, OC(═O)Ra, SRa, S(═O)2Rd, NRbRc or sugar groups (including amino sugar and mono-, di- or poly-saccharides);
• R2 is hydrogen, NH2, —OH, alkyl, substituted alkyl, cycloalkyl, or substituted cycloalkyl;
• each Ra is independently hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, heterocycle, substituted heterocycle, aryl, or substituted aryl;
• Rb and Rc are each independently hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocycle, substituted heterocycle, aryl, substituted aryl, or said Rb and Rc together with the N to which they are bonded optionally form a heterocycle or substituted heterocycle;
• and
• each Rd is independently alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, heterocycle, substituted heterocycle, aryl, or substituted aryl.

A compound characterized by:

• (a) a molecular weight of about 472.62 g/mol;
• (b) a proton nuclear magnetic resonance spectrum substantially the same as that shown in FIG. 1;
• and
• (c) a COSY nuclear magnetic resonance spectrum substantially the same as that shown in FIG. 2.

A method of treating a disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of formula (I),

• or an enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein:
• R1 is hydrogen, halogen, cyano, nitro, CF3, OCF3, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, heterocycle, substituted heterocycle, aryl, substituted aryl, (═O), ORa, OC(═O)Ra, SRa, S(═O)2Rd, NRbRc or sugar group;
• R2 is hydrogen, NH2, —OH, alkyl, substituted alkyl, cycloalkyl, or substituted cycloalkyl;
• each Ra is independently hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, heterocycle, substituted heterocycle, aryl, or substituted aryl;
• Rb and Rc are each independently hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocycle, substituted heterocycle, aryl, substituted aryl, or said Rb and Rc together with the N to which they are bonded optionally form a heterocycle or substituted heterocycle;
• and
• each Rd is independently alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, heterocycle, substituted heterocycle, aryl, or substituted aryl,
• wherein the administration of the compound treats the disorder of the mammal.

A method of inhibiting the growth of an infectious agent, the method comprising contact of the agent with a compound of formula (I)

• or an enantiomer, diastereomer, tautomer, or pharmaceutically-acceptable salt or solvate thereof, wherein:
• R1 is hydrogen, halogen, cyano, nitro, CF3, OCF3, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, (═O), ORa, OC(═O)Ra, SRa, S(═O)2Rd, NRbRc or sugar group;
• R2 is hydrogen, NH2, —OH, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, (preferably hydrogen);
• each Ra is independently hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl;
• Rb and Rc are each independently hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocycle, substituted heterocycle, aryl, substituted aryl, or said Rb and Rc together with the N to which they are bonded optionally form a heterocycle or substituted heterocycle;
• and
• each Rd is independently alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, heterocycle, substituted heterocycle, aryl, or substituted aryl,
• the infective agent being selected from the group consisting of a bacterium, a fungus, a virus, a protozoan, a helminth, a parasite, and combinations thereof.